Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of “Buy” by Brokerages

Shares of Zura Bio Limited (NASDAQ:ZURA) have earned an average rating of “Buy” from the seven brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $15.80.

A number of research analysts have recently issued reports on the stock. HC Wainwright reiterated a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a research note on Tuesday, December 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Leerink Partners assumed coverage on shares of Zura Bio in a report on Monday, November 4th. They set an “outperform” rating and a $15.00 price objective on the stock. Chardan Capital decreased their price target on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Finally, Leerink Partnrs upgraded Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th.

Zura Bio Stock Down 3.9 %

Shares of ZURA stock opened at $1.72 on Friday. The stock has a fifty day moving average price of $2.48 and a 200 day moving average price of $3.46. Zura Bio has a one year low of $1.67 and a one year high of $6.35.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.12). On average, research analysts forecast that Zura Bio will post -0.65 EPS for the current fiscal year.

Insider Transactions at Zura Bio

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 22.10% of the company’s stock.

Institutional Investors Weigh In On Zura Bio

A number of institutional investors have recently modified their holdings of ZURA. AQR Capital Management LLC acquired a new stake in shares of Zura Bio during the 2nd quarter worth $43,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Zura Bio during the 3rd quarter worth approximately $46,000. SG Americas Securities LLC lifted its stake in Zura Bio by 51.6% during the fourth quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock worth $58,000 after purchasing an additional 7,828 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Zura Bio by 51.3% in the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after purchasing an additional 5,900 shares during the last quarter. Finally, Valence8 US LP acquired a new position in Zura Bio during the third quarter worth about $71,000. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.